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explore the cost implications of prescribing Ellipta portfolio in appropriate patients 
versus alternative therapies, in line with clinical guidelines. Methods: a one-year 
BIM was constructed to explore financial implications of prescribing Ellipta medi-
cines as alternative treatment options to currently prescribed therapies. The BIM is 
based on UK prescription analysis, epidemiological and resource data. The BIM uses 
prescription data to generate patient cohorts and progresses them to more intensive 
therapy based on estimates of symptoms of exacerbation or breathlessness. It also 
considers medicines optimsation for patients that could benefit from simplified regi-
mens and estimates the budget impact of moving patients using non-licensed ICS/
LABA to licensed therapies. The model allows definition of treatment progressions, 
using appropriate Ellipta devices to target bronchodilator or steroid based regimens. 
Costs are calculated using market share of current treatments vs. a scenario in which 
Ellipta medicines are used. Differences in patient outcomes, efficacy or safety are not 
explored. Results: It is estimated that the average health economy in the UK has 
5,518 COPD patients of whom 1,320 are eligible to be progressed in their medication. 
In year 1, compared to a base case of utilising the most routinely used existing COPD 
therapies (100% implementation rate for new incident patients and 50% for all oth-
ers) would increase spend by £247,830 compared with a reduced budget impact of 
-£131,920 if these eligible patients were moved to Ellipta medicines. ConClusions: 
The introduction of Ellipta portfolio in COPD could potentially reduce the budget 
impact and total spend on COPD therapies by £379,750 in the average UK health 
economy compared to current prescribing patterns. Funded by GSK
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objeCtives: To conduct the budget impact analysis of Formoterol Easyhaler, which 
allowed to determine the net economic effect of the budget impact in regards of 
replacement of one medicine to another. Methods: Information search was con-
ducted in the public domain. Pharmacoeconomic analysis method – budget impact 
and direct cost analysis were performed. Results: In this study, given the phar-
macoeconomic evaluation of drugs Formoterol Easyhaler, Oxis Turbuhaler, Foradil 
Aerolizer and Atimos. The study had a time horizon of one year. The daily dose of 
formoterol was 24 mcg. Cost analysis was conducted on the cost of basic phar-
macotherapy, compensation costs for treatment of exacerbations, compensation 
costs for side effects and adverse reactions. The total direct cost per patient with 
asthma amounted to 1 262, 17$ to the Easyhaler group, 1 581, 83$ to the Turbuhaler 
group, 1 498,95 and 1 499,99 to the Foradil (30 and 60 doses), and 1 705, 06$ to the 
Atimos. The selection of budget impact method of pharmacoeconomic analysis 
was determined by the advantages of Formoterol Easyhaler in terms of its effi-
ciency and lower value of total direct costs. In the present study, based on the 
results of the “cost analysis” it was revealed that the replacement formoterol of Oxis 
Turbuhaler, Foradil Aerolizer (30 and 60 doses) and Atimos on Easyhaler saved per 
patient respectively 319,66$, 236,78$ (187, 82$ for 60 doses) and 442,89$ for the health 
care system budget. ConClusions: The budget impact analysis results obtained 
in this Formoterol Easyhaler versus others drugs of formoterol comparative study 
demonstrated that Easyhaler therapy resulted in budget saving.
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objeCtives: Allergic rhinitis (AR) is a chronic disease of the upper respiratory tract 
caused by exposure to allergens inducing inflammation of the nasal mucosa and of 
the conjunctiva mediated by antibody Immunoglobulin E (IgE). According to local 
literature, prevalence of symptomatic AR is around 20% and grass pollen is the most 
common allergen causing A (%5 of uncontrolled moderate / severe AR) in Turkey. 
Allergen-specific immunotherapy (AIT) is recommended as a second line treatment 
for patients with moderate to severe allergic rhinitis not or poorly controlled by 
symptomatic treatments.The Five Grass Pollen Sublingual Tablet (5GPST) is an alter-
native AITin Turkey. The aim of this budget impact model (BIM) was to assess the 
cost saving potential of the 5GPST inthe Turkish reimbursement system. Methods: 
Cost calculations were madefrom the payer perspective as per the guidelines of the 
Social Security Institution (SSI). The time horizon considered in the model was one 
year. The clinical data and Rescue Medication Scores were acquired from published 
clinical studies. Direct medical costs were considered in this analysis. Pricing and 
reimbursement prices data are obtained from Ministry of Health Drug Price List and 
the Price List of SSI Health Implementation Guideline. Results: According to the 
BIM, total cost of AR treatment for a patient treated with symptomatic treatment 
alone was 373 TL per year and reached 1.607 TL per year for patients receiving sub-
cutaneous immunotherapy. Total cost of AR with5GPSTwith %11discount for the first 
reimbursement year was 1.168 TL. Total yearly cost of AR with 5GPST with % 41 dis-
count was 864 TL. ConClusions:: Compared to subcutaneous AIT, 5GPST is a cost 
saving alternative fortreatment of seasonal AR in Turkey from a SSI perspective. The 
treatment is 27% or 46% cheaper applying 11% or 41% discount rates respectively.
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mixed-treatment comparison) were applied at 2 weeks. Lung function decline after 
2 weeks was applied independent of treatment arm but dependant on GOLD stage. 
Exacerbation risk, health outcomes and costs of COPD management were calculated 
based on GOLD stage. Cost inputs were taken from published literature. Results: 
The 5-year budget impact of displacement of tiotropium by tiotropium + olodaterol 
Respimat®was a cost-saving of £25.8 million, £2.7 million, £1.6 million, and £0.9 
million, in England, Scotland, Wales, and Northern Ireland respectively. These 
cost-savings were largely driven by a predicted 0.8% reduction in COPD manage-
ment costs, and a predicted 0.9% reduction in the costs of exacerbation manage-
ment. ConClusions: Switching patients with COPD from tiotropium maintenance 
to tiotropium + olodaterol Respimat® maintenance therapy has the potential to 
be cost-saving to the UK NHS. These cost-savings largely result from a predicted 
reduction in primary and secondary care costs. Whilst treatment switching should 
be driven by clinical rationale and patient preference, this finding has implications 
for medicine optimisation in the UK.
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On unScheduled healthcaRe cOStS and InhaleR SatISfactIOn
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objeCtives: Spiriva® Handihaler® (tiotropium) is a single capsule dry powder 
inhaler (DPI) for the treatment of COPD. A budget impact model was developed 
to assess the potential economic impact of introducing an inhaler with improved 
features compared to Spiriva® Handihaler®to treat COPD in the UK. The potential 
cost benefit of increasing treatment satisfaction, due to the improved characteris-
tics of this new inhaler was investigated. Methods: The eligible patient popula-
tion presented was based on the number of confirmed COPD diagnoses in the UK, 
with the proportion of patients receiving Spiriva® Handihaler® based on market 
research data. The costs of scheduled and unscheduled healthcare events presented 
within the model were taken from publically available UK sources. Findings from a 
multinational, cross-sectional, real-world survey of 1,443 COPD patients associat-
ing inhaler attributes, inhaler satisfaction, adherence and patient health status 
were used within the model to determine the correlations between inhaler sat-
isfaction, treatment adherence and unscheduled healthcare events. Using these 
correlations, an annual number of UK unscheduled healthcare events associated 
with COPD was calculated for patients using a new improved inhaler and Spiriva® 
HandiHaler®. Results: The annual UK costs of treating COPD patients for unsched-
uled healthcare events were € 1027.05 with Spiriva® HandiHaler®vs. € 922.14 with 
the new inhaler. Potential budgetary savings achieved by using the new inhaler 
instead of HandiHaler® were calculated at € 104.91 per patient and € 16.69 million 
for the UK COPD patient population per year. ConClusions: There is a potential 
for a new improved tiotropium inhaler to offer budgetary savings compared with 
Spiriva® Handihaler® resulting from cost benefits due to increased patient satis-
faction with their inhaler.
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objeCtives: This study estimated the total expenditure on prescribed Seasonal 
Allergic Conjunctivitis (SAC) medication in the UK and the budget impact of switch-
ing patients to alternative treatments. Methods: A budget impact model devel-
oped from the UK NHS and Personal Social Services (PSS) perspective was used 
to evaluate total spending on: olopatadine, generic sodium cromoglicate, branded 
sodium cromoglicate, nedocromil sodium. A 4-month time horizon was applied 
(average allergy season duration). Direct to patient data (National Health and 
Wellness Survey [NHWS]) were used to estimate the number of patients receiving 
prescription SAC treatment. Published 42-day efficacy data were input for each 
product, with patients classified as either successfully treated or unsuccessfully 
treated at 14, 28, 42, and 120 days. Unsuccessful treatment required additional 
resource use and switch to further therapy. Two approaches extrapolated clinical 
data to 120 days: A) No decline after 42-days, B) linear decline in efficacy. Cost per 
treatment was estimated and multiplied by its market size to estimate the total 
current spend in the UK. Model structure and inputs were validated with clinical 
KOLs. Results: Under scenario A olopatadine treatment was associated with the 
lowest cost. Olopatadine spending over a four month period was £100.08 versus 
£104.39 for sodium cromoglicate. Under scenario B, sodium cromoglicate treatment 
resulted in costs of £114.97 versus £124.07 with olopatadine. An estimated 3,161,807 
UK adults are treated in the Rx market (NHWS). Total spending was estimated to 
exceed £300,000,000 under all scenarios. Under scenario A switching all patients 
to olopatadine may result in savings of £15,378,769. ConClusions: Increasing 
olopatadine market share in SAC may be cost-saving when compared against alter-
native treatments for SAC. The use of direct to patient surveys are an important 
source in market sizing when considering markets split across prescription and 
over-the-counter treatments.
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BudgetaRy ImPlIcatIOnS Of IntROducIng the gSk ellIPta PORtfOlIO 
fOR cOPd In the uk
Harding TL, Thompson G, Mulley PJ
GlaxoSmithKline, London, UK
objeCtives: The GSK Ellipta portfolio medicines are licensed for treatment of COPD 
in the UK and is comprised of fluticasone furoate/vilanterol, umeclidinium bromide/
vilanterol and umeclidinium bromide. A budget impact model (BIM) was designed to 
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clInIcal and ecOnOmIc BenefItS aSSOcIated WIth leSS uSe Of 
flutIcaSOne In PedIatRIc PatIentS WIth PeRSIStent aSthma tReated 
WIth hIgh dOSeS Of SPecIfIc alleRgen ImmunOtheRaPy tO mIteS
Polanco C
Merck, Madrid, Spain
objeCtives: The existing guidelines recommend the minimum effective dose of 
inhaled corticosteroids in children with persistent asthma. Clinical studies and 
recent Cochrane reviews stablish the existence of a significant difference in the 
growth rate of pediatric patients that receive corticoids against those who do not 
receive them1-5. Another study showed that pediatric patients treated with sub-
cutaneous immunotherapy (IT) to house dust mites required a significant lower 
dose of fluticasone propionate (PF). Quantify the savings associated with the dose 
decrease of PF in pediatric patients with allergic asthma treated for three years 
with high dose specific-allergen immunotherapy to mites Methods: The average 
reduction of PF comes from an observational, randomized, three years prospective 
study (N= 65; 33 treated with IT+FP). The number of containers per patient were 
calculated as well as its economical savings regarding the baseline situation. The 
immunotherapy used and the PF were accounted for by means of RRP. Results: 
The PF accumulated savings is equivalent to 29,3% of the immunotherapy phar-
macological costs. Since PF is a reduced contribution medication, the savings for 
the NHS are 44,9%-67,3% and 5,9%-3,9% for the patient depending on the income 
range. ConClusions: Adding high dose specific-allergen immunotherapy to mites 
to pharmacological treatment retains control over the allergic asthma and reduces 
the use of corticoids, consequently minimizing the impact on the growth rate of 
the patients and generates economical savings.
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objeCtives: To calculate the fluctuation in the drug cost involved in the treatment 
of Chronic Obstructive Pulmonary Disease (COPD) during 2013-2015. Methods: 
Standard treatment guidelines (STG), 4th edition were perused to understand the 
management of COPD. Current Index of Medical Specialities (CIMS) Oct - Jan 2013, 
2014 and 2015 issue were used to capture the price of drugs. One day cost of treat-
ment and its variation was studied. Results: According to STG, drugs needed 
for the maintenance treatment of COPD includes Salbutamol inhaler 200mcg 4 
times a day or Terbutaline 250mcg inhaler, Ipratropium bromide 200mcg inhaler 
2 times a day, Theophylline 100mg tablets 3 times a day, Amoxicillin + Clavulanic 
acid (500mg + 125mg) injection 3 times a day, Fluticasone 100mcg inhalation once 
a day, Montelukast tablet 5mg once a day. The minimum and maximum difference 
in cost of one day maintenance was found to be 136%, 182% and 169% in the year 
2013, 2014 and 2015 respectively. This fluctuation was observed by totaling the price 
of all the drugs mentioned above. ConClusions: Wide variation exists between 
the minimum and maximum cost of maintainance therapy of COPD. Government 
should take some step in order to regulate and to bring uniformity in price. So that it 
can be affordable by a common man which will ultimately improve the compliance 
and reduce the economic burden.
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tO Study the clInIcal chaRacteRIStIcS, tReatment PatteRn 
and factORS aSSOcIated WIth the tOtal hOSPItal cOSt In acute 
ReSPIRatORy dIStReSS SyndROme In teRtIaRy caRe hOSPItal
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objeCtives: To analyze the clinical symptoms, treatment pattern, outcomes and 
factors associated with total cost of treatment. Methods: A retrospective cross 
sectional study was conducted in tertiary care hospital. The patient details such as 
demographical data, clinical features, treatment and outcome were collected from 
the Medical Records Department. The total cost of treatment was collected from 
Finance Department. Data were analyzed by using SPSS 20.0 Results: Mean age of 
the study population was found to be 42.7±18.2 year with majority of male 94(52.2%). 
Sepsis (59(32.8%)) was the most common etiology for ARDS in our study population. 
Analysis of 180 cases showed that total number of hospitalization days were 1793 
and total cost of treatment was 11,005,448 INR. The patients who received corticos-
teroid therapy before 48 hours had better recovery rate. Mean ventilation days in the 
group of patients who received early glucocorticoid therapy were less (9.29±6.06) 
then those who received late therapy (13.64±6.03) ConClusions: Mortality rate 
associated with ARDS was relatively high. Management with steroids has no special 
benefit in reduction in mortality rate. Time of start of steroid therapy plays an impor-
tant role in the management and was observed that early start of steroid therapy 
showed better recovery rate as well as reduction in hospitalization and ventilation 
days. The total treatment cost for the management of ARDS is relatively high.
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objeCtives: Retrospective database studies of PAH using US payer claims data 
have limitations due to lack of specific ICD-9 codes for PAH and ability to identify 
patient severity. A previous study validated an algorithm including patients with 
non-specific PH codes and a claim for an advanced PAH drug therapy. This study used 
provider-reported disease severity – FC – to examine the impact of FC on healthcare 
objeCtives: Knowing the burden of community-acquired pneumonia (CAP) 
is important for taking preventive measures. This study aimed to calculate 
the direct costs of CAP in adults > 18 years old. Methods: Data of outpatients 
and inpatients with CAP from 18-month period were retrospectively evaluated. 
Numbers of radiological and laboratory analyses, hospital stay (day), and spe-
cialist visits were multiplied by the relevant unit costs and the cost per patient 
was calculated. Total drug costs were calculated by multiplying daily drug cost 
with medication day for each drug for inpatients and by based on packet price 
of each drug for outpatients. Costs were expressed as median (minimum-max-
imum). Results: The mean ages were 61.56±17.87 years in inpatients (n= 208, 
51.4% males) and, 53.78±17.46 years in outpatients (n= 211, 53.6% males). The 
ratios of being ≥ 65 years old in inpatients and outpatients were 48.6% and 28.9%, 
respectively. Among inpatients, 36.5% had chronic obstructive pulmonary disease 
(COPD) and18.3% had hypertension. Among outpatients, 22.7% had COPD and 
20.4% had asthma. The total cost was 300.01€ (75.11€ -9,870.16€ ) for inpatients 
and 39.43€ (5.34€ -230.34€ ) for outpatients. Drug cost had the highest share of 
total cost both in inpatients and outpatients. In inpatients, total cost was 345.21€ 
(75.11€ -9,870.16€ ) in those ≥ 65 years old and 283.35€ (79.13€ -3,785.71€ ) in those 
< 65 years old (p= 0.014); this difference was not found in outpatients. The total 
cost was 633.73€ (313.11€ -4,375.23€ ) in inpatients hospitalized more than once and 
270.67€ (75.11€ -9,870.16€ ) in those hospitalized once (p< 0.001). In inpatients with 
and without comorbidities, total costs were 308.14€ (75.11€ -9,870.16€ ) and 221.08€ 
(92.20€ -3785.71€ ), respectively (p= 0.016). In outpatients with and without comor-
bidities, total costs were 44.97€ (5.34€ -230.34€ ) and 26.56€ (5.34€ -110.96€ ), respec-
tively (p< 0.001). ConClusions: Costs were higher in patients with advanced 
age, having comorbidity, and hospitalized more than once. For decreasing the 
economic burden of CAP on healthcare system, preventive measures should be 
taken.
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objeCtives: The purpose of this study was to estimate short-term medical cost 
savings, including costs not directly associated with Smoking Cessation Outpatient 
Visits (SCOVs), from claims data of employee based public health insurance in 
Japan. Methods: We conducted two analyses using claims data from January 
2005 to December 2013 provided by Japan Medical Data Center Co., Ltd. In the 
first analysis, we compared medical costs composed of inpatient, outpatient, and 
medications of the SCOV group, smokers having SCOVs, with those of non-SCOV 
group for each year. The first day of index year 0 is the day of first SCOV for the 
SCOV group and is the day after one observation year for the non-SCOV group. 
In the second analysis, among smokers with SCOVs, a mean increase ratio of 
medical costs was calculated, varying by the number of SCOVs. Results: In the 
first analysis, medical costs per patient per years (PPPYs) of the SCOV group were 
¥95,200 at year -1, ¥173,400 at year 0, ¥130,900 at year 1 and ¥116,100 at year 5, and 
PPPYs of non-SCOV group were ¥95,200 at year -1, ¥100,700 at year 0, ¥108,100 at 
year 1 and ¥125,900 at year 5. The PPPY of SCOV group at year 0 was higher than 
that of non-SCOV group at year 0 but the relation was reversed at year 5. In the 
second analysis, the mean increase ratio of medical costs of the one-SCOV group 
was the highest, 58%, and that of five-SCOV group was the smallest, 34%. This 
measure showed a downward trend. ConClusions: Results are suggestive of 
a possibility that the future medical costs of patients with smoking cessation 
outpatient visits are lower than those without smoking cessation outpatient visit 
and increasing the number of smoking cessation outpatient visits decreases the 
mean increase ratios of medical costs.
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objeCtives: To evaluate the cost efficiency of preventive treatment with OM 85 in 
patients with AR, asthma and COPD compared to the same patients the previous 
year only receiving standard of care. Methods: This multi-centre, clinical trial was 
conducted in Argentina in 2010. Eighty-four patients with COPD, allergic rhinitis 
(AR) and asthma aged 16-65 years who had not received a bacterial lysate in 2009 
were included. In 2010, the same patients received OM-85 bacterial lysate capsule. 
Capsules were administered daily for 10 consecutive days per month for a duration 
of 3 consecutive months. Results: the number of reinfections and exacerbations 
in the OM 85 arm was decreased from 85% to 45.5% (p< 0.05) and from 65.7% to 
34.9% (p< 0.05) vs the previous year, respectively. Hospitalizations were 2% in the 
OM 85 group and 12% for the previous year. The average total cost per patient per 
month with AR caused by reinfections and exacerbations was 448.9 ARS and 269.9 
ARS in the OM 85 arm compared to 660.40 ARS and 574.40 ARS in the previous year. 
In patients with asthma total cost for reinfections and exacerbations was 487.9 ARS 
and 473.9 ARS in the OM 85 arm compared to 1’144 ARS and 970 ARS in the previ-
ous year. Reinfections and exacerbations total cost in COPD patients was 1356.5 
ARS and 1217.5 ARS in the OM 85 patients but amounted to 1’708.2 ARS and 1599.6 
ARS, respectively, in the previous year. ConClusions: Preventive treatment with 
OM 85 in patients with allergic rhinitis, asthma and COPD significantly reduces 
reinfections rates, exacerbations and hospitalizations compared to the previous 
year. Associated cost savings have been substantial and ranged from 15% to 60% vs 
previous year (no prophylaxis).
